Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80°C in factor VIII

Vox Sanguinis

Volumn 92, Issue 1, 2007, Pages 56-63

  Roberts, P L ^a   Dunkerley, C ^a   McAuley, A ^a   Winkelman, L ^a  

^a BIO PRODUCTS LABORATORY   (United Kingdom)

Author keywords

Dry heat; Factor VIII; Process parameters; Virus inactivation

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8Y;

ARTICLE; DRUG MANUFACTURE; FREEZE DRYING; HYPERTHERMIC THERAPY; NONHUMAN; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS INACTIVATION; VIRUS INFECTIVITY;

DECONTAMINATION; DRUG CONTAMINATION; FACTOR VIII; FREEZE DRYING; HEAT; HUMANS; PHARMACEUTICAL PREPARATIONS; VIRUS INACTIVATION;

EID: 33845657410     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2006.00845.x     Document Type: Article

References (25)

1. Burnouf T, Radosevich M: Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000; 14:94-110
2. Foster PR, Cuthbertson B: Procedures for the prevention of virus transmission by blood products; in Madhok R, Forbes D, Evatt BL (eds): Blood, Blood Products and HIV. London, Chapman and Hall, 1994:207-248
3. Roberts P: Virus safety plasma products. Rev Med Virol 1996; 6:25-38
4. Edsall JT: Stabilization of serum albumin to heat, and inactivation of the hepatitis virus. Vox Sang 1984; 46:338-340
5. Winkelman L, Feldman PA, Evans DR: Severe heat treatment of lyophilised coagulation factors. Curr Stud Hematol Blood Transfus 1989; 56:55-69
6. Study group of the UK haemophilia centre directors on surveillance of virus transmission by concentrates: Effect of dry heating of coagulation factor concentrates at 80°C for 72 hours on transmission of non-A, non-B hepatitis. Lancet 1988; ii:814-816
7. Winkelman L, Owen NE, Evans DR, Evans H, Haddon ME, Smith JK, Prince PJ, Williams JD, Lane RS: Severely heated therapeutic factor VIII concentrate of high specific activity. Vox Sang 1989; 57:97-103
8. Fisher KA: A new method for the analytical determination of the water content of liquids and solids. Angew Chem 1935; 48:394-396
9. Winkelman L, McAuley A, Sims G, Abbott B, McPhee J: Residual water content in a lyophilised, heated coagulation factor concentrate; in Smit Sibinga CT, Das PC, Meryman MT (eds): Cryopreservation and low temperature biology in blood transfusion. 14th International Symposium on Blood Transfusion. Developments in Haematology and Immunology 1990; 24:215-224
10. Gornall AC, Baradwill CJ, David MM: Determination of serum protein by means of the Biuret reaction. J Biol Chem 1949; 177:751-766
11. Rizza CR, Fletcher ML, Kernoff PB: Confirmation of viral safety of dry heated factor VIII concentrate (8Y) prepared by Bio Products Laboratory (BPL): a report on behalf of U.K. Haemophilia Centre Directors. Br J Haematol 1993; 84:269-272
12. Skidmore SJ, Pasi KJ, Mawson SJ, Williams MD, Hill FG: Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis. J Med Virol 1990; 30:50-52
13. Williams MD, Cohen BJ, Beddall AC, Pasi KJ, Mortimer PP, Hill FG: Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang 1990; 58:177-181
14. Roberts P, McAuley A, Dunkerley C, Winkelman L: Virus inactivation during severe heat treatment of a lyophilised factor VIII concentrate. Thromb Haemost 1991; 65:1163
15. Committee for Proprietary Medicinal Products, European Medicines Evaluation Agency: Note for guidance on plasma-derived medicinal products. CPMP/BWP/269/95 rev 3, 2001
16. Savage M, Torres J, Franks L, Masecar B, Hotta J: Determination of adequate moisture content for efficient dry heat viral inactivation in lyophilized factor VIII by loss on drying and by near infrared spectroscopy. Biologicals 1998; 26:119-240
17. Roberts PL, Hart H: Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates. Biologicals 2000; 28:185-188
18. Kasper CK, Brooker M: Registry of Clotting Factor Concentrates, 7th edn. Published by the World Federation of Haemophilia, Montreal, Canada, 2006
19. Oates A, Polmear E, Herrington R, Farrugia A, Sykes S, Raines G, Aumann H, Street A: von Willebrand factor characterization of a severe dry heat treated factor VIII concentrate, AHF (high purity). Thromb Res 1992; 65:389-399
20. Hart HF, Hart WG, Crossley J, Perrie AM, Wood DJ, John A, McOmish F: Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates. Vox Sang 1994; 67:345-350
21. Powell JS, Bush M, Harrison J, Abildgaard C, Vosburgh E, Thompson AR, Hurst D: Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A. Haemophilia 2000; 6:140-149
22. Arrighi S, Rossi R, Borri MG, Lesnikov V, Lesnikova M, Franco E, Divizia M, De Santis ME, Bucci E: 'In vitro' and in animal model studies on a double virus-inactivated factor VIII concentrate. Thromb Haemost 1995; 74:868-873
23. Stadler M, Gruber G, Kannicht C, Biesert L, Radomski KU, Suhartono H, Pock K, Neisser-Svae A, Weinberger J, Romisch J, Svae TE: Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate®). Biologicals 2006. doi: 10.1016/j.biologicals. 2005.11.010
24. Dichtelmuller H, Rudnick D, Breuer B, Kotitschke R, Kloft M, Darling A, Watson E, Flehmig B, Lawson S, Frosner G: Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C. Biologicals 1996; 24:125-130
25. Roberts PL: Severe heat treatment of freeze-dried coagulation factor concentrates: is hotter necessarily better? Vox Sang 1995; 68:61-62